Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $PTCT
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/11/2025 | $41.00 → $55.00 | Underperform → Neutral | BofA Securities |
3/7/2025 | $55.00 | Sector Perform | Scotiabank |
12/13/2024 | $45.00 → $67.00 | Equal-Weight → Overweight | Morgan Stanley |
12/3/2024 | $39.00 → $63.00 | Sector Perform → Outperform | RBC Capital Mkts |
10/10/2024 | Mkt Perform | Raymond James | |
9/4/2024 | $44.00 | Outperform | Robert W. Baird |
8/26/2024 | $47.00 | Buy | UBS |
5/20/2024 | Underperform → Mkt Perform | Raymond James |
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., March 28, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that on March 24, 2025, the company approved non-statutory stock options to purchase an aggregate of 12,000 shares of its common stock and 28,220 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 35 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on Ma
PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe
WARREN, N.J., March 28, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the European Commission (EC) has adopted the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) to not renew the authorization of Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy. While this action effectively removes the drug's conditional marketing authorization in the European Economic Area, the EC indicated that individual countries within the European Union can leverage Articles 117(3) and 5(1) of the EU Directive 2001/83 to allow continued use of Translarna. "We are of course disappointe
PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies
— Results show 97% of phenylalanine (Phe) tolerance study participants were able to increase their dietary Phe intake with a mean increase of 126% — — Genetic variant analysis of Phase 3 APHENITY trial demonstrates meaningful effect in classical subjects with non-BH4 responsive genotypes — WARREN, N.J., March 20, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today shared new data being presented from the Phase 3 APHENITY trial and subsequent open-label extension study at the 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. These data provide further evidence of the potential meaningful benefits of sepiapterin treatment for the full s
PTC Therapeutics upgraded by BofA Securities with a new price target
BofA Securities upgraded PTC Therapeutics from Underperform to Neutral and set a new price target of $55.00 from $41.00 previously
Scotiabank initiated coverage on PTC Therapeutics with a new price target
Scotiabank initiated coverage of PTC Therapeutics with a rating of Sector Perform and set a new price target of $55.00
PTC Therapeutics upgraded by Morgan Stanley with a new price target
Morgan Stanley upgraded PTC Therapeutics from Equal-Weight to Overweight and set a new price target of $67.00 from $45.00 previously
Gravier Pierre bought $198,736 worth of shares (7,700 units at $25.81), increasing direct ownership by 30% to 33,700 units (SEC Form 4)
4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
CHIEF BUSINESS OFFICER Pauwels Eric sold $630,104 worth of shares (11,220 units at $56.16), decreasing direct ownership by 13% to 72,640 units (SEC Form 4)
4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
Director Okey Stephanie sold $270,000 worth of shares (5,000 units at $54.00), decreasing direct ownership by 36% to 8,867 units (SEC Form 4)
4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
EXEC. VP AND CLO Boulding Mark Elliott exercised 15,521 shares at a strike of $33.02 and sold $827,233 worth of shares (15,521 units at $53.30) (SEC Form 4)
4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
PTC Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)
SEC Form 144 filed by PTC Therapeutics Inc.
144 - PTC THERAPEUTICS, INC. (0001070081) (Subject)
SEC Form 144 filed by PTC Therapeutics Inc.
144 - PTC THERAPEUTICS, INC. (0001070081) (Subject)
November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency
For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f
Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors
BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sensorium Therapeutics (Sensorium), a biotechnology company translating insights from nature and human experience to deliver transformational therapeutics, today announced the appointment of veteran life sciences executive David Southwell to its Board of Directors. "We are excited to welcome David to our Board," said Dick Simon, Chief Executive Officer of Sensorium. "He is a seasoned life sciences executive with a track record of success that spans multiple therapeutic areas and development stages. David's depth of experience will be a key asset as we advance our lead program, SENS-01, towards the clinic and expand our drug pipeline into addition
PTC Therapeutics Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer
SOUTH PLAINFIELD, N.J., July 17, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced the appointment of Pierre Gravier to the role of Chief Financial Officer (CFO). Mr. Gravier brings more than 17 years of experience as an investment banker, venture capitalist and scientist to PTC. Most recently, Pierre was a managing director in the healthcare group of Perella Weinberg Partners, a leading independent global advisory firm. At Perella Weinberg, he focused on advising companies in the biopharmaceutical and pharmaceutical sectors on finance strategy and corporate development. "We are incredibly excited to have Pierre as part of PTC's leadership team," said Matthew B. Klein
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
– Full year 2024 revenue of $807 million, exceeding guidance – – All 2024 clinical and regulatory milestones were achieved on schedule, including four NDA submissions, all of which were accepted for filing – – License and collaboration agreement with Novartis for PTC518 Huntington's disease program closed in January 2025 – – Cash of over $2.0 billion as of January 2025 – WARREN, N.J., Feb. 27, 2025 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced a corporate update and financial results for the fourth quarter ending December 31, 2024. "Our strong fourth quarter rounds out a year of significant accomplishment across every part of our company," said Matthew B. Klein, M.
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results
WARREN, N.J., Feb. 13, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full year 2024 financial results and provide an update on the company's business and outlook on Thursday, Feb. 27, at 4:30 p.m. EST. To access the call by phone, please click here to register and you will be provided with dial-in details. To avoid delays, we recommend participants dial in 15 minutes prior to the start of the call. The webcast conference call can be accessed on the Investor section
PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program
- PTC to receive $1.0B in cash at closing -- PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones -- PTC to share profits in the U.S. and tiered double-digit royalties on ex-U.S. net sales -- Novartis will assume global development, manufacturing and commercial responsibilities following completion of placebo-controlled portion of ongoing PIVOT-HD study -- PTC will host a conference call on Dec. 2, 2024, at 8:30 am EST- WARREN, N.J., Dec. 2, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NY
Amendment: SEC Form SC 13G/A filed by PTC Therapeutics Inc.
SC 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)
Amendment: SEC Form SC 13G/A filed by PTC Therapeutics Inc.
SC 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)
Amendment: SEC Form SC 13G/A filed by PTC Therapeutics Inc.
SC 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)